Across TCGA pan-cancer cohorts, SHC4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SHC4 data layer compared with 29 for mass-spec protein and 1 for mass-spec protein.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher SHC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SHC4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
LUAD, UCEC, and SARC are the cancer types where SHC4 Mutation most reproducibly stratifies survival.